Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat diabetes and obesity, but research has shown they can also influence other behaviors, such as promoting impulse control and reducing substance and alcohol use. This occurs through potential interactions with the brain's reward and stress systems. Researchers from Rutgers University analyzed data from a nationally representative U.S. study conducted in 2025, includin…
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are commonly used to treat diabetes and obesity, but research has shown they can also influence other behaviors, such as promoting impulse control and reducing substance and alcohol use. This occurs through potential interactions with the brain's reward and stress systems. Researchers from Rutgers University analyzed data from a nationally representative U.S. study conducted in 2025, includin…